Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Mar 2024)

Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept

  • Massimo Imazio,
  • Allan L. Klein,
  • Antonio Brucato,
  • Antonio Abbate,
  • Michael Arad,
  • Paul C. Cremer,
  • Antonella Insalaco,
  • Martin M. LeWinter,
  • Basil S. Lewis,
  • David Lin,
  • Sushil A. Luis,
  • Stephen J. Nicholls,
  • Paul Sutej,
  • Yishay Wasserstrum,
  • JoAnn Clair,
  • Indra Agarwal,
  • Sheldon Wang,
  • John F. Paolini

DOI
https://doi.org/10.1161/JAHA.123.032516
Journal volume & issue
Vol. 13, no. 6

Abstract

Read online

Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology and Outcomes Study). The RHAPSODY long‐term extension further explored recurrent pericarditis natural history and treatment duration decision‐making during 24 additional months of open‐label rilonacept treatment. Methods and Results Seventy‐four patients commenced the long‐term extension, with a median (maximum) total rilonacept duration of 22 (35) months. Individually, 18 months after the most proximal pericarditis recurrence, investigators decided to continue rilonacept on study, suspend rilonacept for off‐treatment observation (rescue allowed), or discontinue the study. The annualized incidence of pericarditis recurrence on rilonacept up to the 18‐month decision milestone was 0.04 events/patient‐year versus 4.4 events/patient‐year prestudy while on oral therapies. At the 18‐month decision milestone, 64% (33/52) continued rilonacept, 15% (8/52) suspended rilonacept for observation, and 21% (11/52) discontinued the study. Among the 33 patients (1/33; 3.0%) continuing rilonacept (median time to recurrence could not be estimated due to too few events), a single recurrence occurred 4 weeks after a treatment interruption. Among patients suspending rilonacept, 75% (6/8) experienced recurrence (median time to recurrence, 11.8 weeks [95% CI, 3.7 weeks to not estimable]). There was a 98% reduction in risk of pericarditis recurrence among patients continuing rilonacept treatment after the 18‐month decision milestone versus those suspending treatment for observation (hazard ratio, 0.02; P<0.0001). Conclusions In the RHAPSODY long‐term extension, continued rilonacept treatment resulted in continued response; treatment suspension at the 18‐month decision milestone was associated with pericarditis recurrence. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03737110.

Keywords